TG Therapeutics Post-IPO capital

TG Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with B-cell malignancies and autoimmune diseases. The company's pipeline includes a combination of novel small molecules and antibodies designed to target key pathways involved in these diseases. Their lead programs, ublituximab and umbralisib, are being investigated in various hematologic cancers and autoimmune conditions.